Amazon health and beauty 2026 H1 review, suppression rates by sub-vertical and the brands most exposed

Amazon suppressed 14.7% of active health and beauty ASINs at least once in H1 2026. That is the headline number from our cross-client review of 4,200 ASINs across 31 brands. It is the highest suppression rate we have measured in any half-year since we started tracking in 2022.

The category average hides everything that matters. Suppression in topical OTC ran at 27.3%. Suppression in color cosmetics ran at 4.1%. The brands at the top of the exposure curve are not the brands you would guess from category alone, they are the brands with a specific operating profile that Amazon’s 2026 enforcement model punishes.

Suppression rates by sub-vertical, H1 2026

The numbers are first-party from our client cohort. Range reflects the spread between the lightest and heaviest enforcement weeks in the half.

Topical OTC (drug-facts panel SKUs): 27.3% of ASINs suppressed at least once. Range 18% to 41% by week. Drivers: drug-facts panel inconsistencies between A+ and main image, “clinically proven” without an NDA-tier study, and SKUs that crossed the OTC/cosmetic line in claim language.

Supplements (capsules, gummies, powders): 19.6% suppressed. Range 14% to 28%. Drivers: structure-function claims that read as disease claims, missing “These statements have not been evaluated by the FDA” disclaimer, and aggressive front-end Cosmo-bait that triggered automated review.

Skin care (anti-aging, acne, sun): 16.2% suppressed. Range 11% to 24%. Drivers: SPF claims without third-party validation on file, “reverses” and “eliminates” language, and before-after imagery that crossed Amazon’s testimonial guideline.

Personal care (oral, hair, body wash): 8.9% suppressed. Range 6% to 13%. Drivers: ingredient-free claims (“sulfate-free”) that Amazon could not verify against the supplied COA.

Color cosmetics: 4.1% suppressed. Range 2% to 7%. Lowest in category. Suppression here is almost entirely driven by image policy violations, not claim policy.

The pattern is clean. The closer your SKU is to a drug, by claim, by ingredient, or by use case, the higher your suppression rate. The 2026 enforcement model has compressed the ambiguity zone to almost nothing.

The four brand profiles most exposed in H2

Sub-vertical is the loud variable. Brand operating profile is the quiet one. Across the cohort, four operating profiles took 73% of the total suppression hours.

Profile 1: The single-warehouse supplement brand running 60+ SKUs on a thin compliance file. Average suppression rate in cohort: 31%. These brands launched fast, scaled SKUs faster, and never built per-SKU COAs or per-claim documentation. Amazon’s 2026 model audits per-SKU. The thin file becomes the bottleneck.

Profile 2: The legacy topical OTC brand that has not refreshed A+ since 2023. Average suppression rate: 24%. The 2023 A+ template was approved against a different enforcement model. Drug-facts panels are inconsistent across SKU variants. Amazon’s automated review catches the inconsistency, not the underlying compliance.

Profile 3: The DTC-first skincare brand using marketing-team copy on Amazon. Average suppression rate: 18%. The DTC site can say “reverses sun damage.” Amazon cannot. Brands that copy-paste the .com hero copy into the listing get suppressed in week two.

Profile 4: The brand that just expanded internationally and pulled US listings into the new marketplace template. Average suppression rate: 21%. The international template often re-introduces claim language the US team already cleaned up. The cross-marketplace audit nobody runs is the highest-ROI compliance project of 2026.

The full enforcement pattern behind these numbers is documented in FDA-restricted claim language on Amazon, the 2026 enforcement pattern. The post above explains the why; the numbers in this post are the operational impact.

What changed in the enforcement model

Three operational shifts drove the H1 suppression spike. First, Amazon’s automated review now cross-references A+ image text against listing bullets and brand-store claims. Inconsistency between surfaces is a flag. Second, Cosmo’s retrieval data is now fed back into the review pipeline, claims that retrieve well but cannot be supported get prioritized for human review. Third, the appeals window for claim suppression dropped from a typical 7-day resolution in 2024 to a typical 21-day resolution in March 2026. The cost of getting suppressed has tripled in lost-session terms.

None of this is announced. All of it is measurable in the data.

What the operator should do this quarter

Three actions, in order. Run a per-SKU compliance file audit and flag any SKU where the supporting documentation is older than 24 months or thinner than three pages. Run a cross-surface claim audit comparing A+ image text, A+ HTML, listing bullets, brand store, and any international marketplace listing for the same SKU, every inconsistency is a flag. Then run the appeals queue review: pull every suppressed ASIN from the last 90 days, classify by suppression reason, and rebuild the documentation chain so the next suppression resolves in days, not weeks.

Brands that do all three exit H2 with suppression rates in the 4% to 8% band even in topical OTC. Brands that do none of the three stay in the 20%+ band and lose H2 to appeals work that should have been H1 prep work.

If you want our H1 review applied to your specific brand profile and SKU set, Subscribe to the Operator Brief. Each issue runs one sub-vertical’s enforcement pattern with the operator-grade detail above and the per-SKU action list.